Aura Biosciences Appoints Sapna Srivastava, Ph.D., to its Board of Directors
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aura Biosciences, a clinical-stage oncology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the appointment of Sapna Srivastava, Ph.D., to its Board of Directors. “Sapna is a recognized leader in the biopharmaceutical industry with over two decades of broad experience in corporate and financial strategy,” said David Johnson, Chairman of the Board of Aura Biosciences. “We welcome S